Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03026348 |
Recruitment Status :
Completed
First Posted : January 20, 2017
Last Update Posted : August 31, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Respiratory Syncytial Viruses | Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant Biological: RSV F Vaccine Biological: Matrix-M1 Adjuvant Other: Phosphate Buffer | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults |
Study Start Date : | January 2017 |
Actual Primary Completion Date : | April 2017 |
Actual Study Completion Date : | May 18, 2018 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Treatment Group A
Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
|
Biological: RSV F Vaccine Other: Phosphate Buffer |
Active Comparator: Treatment Group B
Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
|
Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant Other: Phosphate Buffer |
Active Comparator: Treatment Group C
Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
|
Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant |
Active Comparator: Treatment Group D
Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
|
Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant Other: Phosphate Buffer |
Active Comparator: Treatment Group E
Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
|
Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant |
Active Comparator: Treatment Group F
Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
|
Biological: RSV F Vaccine Biological: Matrix-M1 Adjuvant Other: Phosphate Buffer |
Active Comparator: Treatment Group G
Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
|
Biological: RSV F Vaccine Biological: Matrix-M1 Adjuvant |
Active Comparator: Treatment Group H
Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
|
Biological: RSV F Vaccine Biological: Matrix-M1 Adjuvant Other: Phosphate Buffer |
Active Comparator: Treatment Group J
Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
|
Biological: RSV F Vaccine Biological: Matrix-M1 Adjuvant |
Active Comparator: Treatment Group K
Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
|
Biological: RSV F Vaccine Biological: Matrix-M1 Adjuvant Other: Phosphate Buffer |
Active Comparator: Treatment Group L
Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
|
Biological: RSV F Vaccine Biological: Matrix-M1 Adjuvant |
Placebo Comparator: Treatment Group M
Day 0 Phosphate Buffer Day 21 Phosphate Buffer
|
Other: Phosphate Buffer |
- Neutralizing antibody titers to at least one RSV/A strain [ Time Frame: Day 0, 21, 28 ]
- Subjects with solicited local and systemic AEs occurring within the 7-day period following dosings on Day 0 and Day 21 and all adverse events, solicited and unsolicited, occurring within the 56-day period of Day 0. [ Time Frame: Day 0 - Day 6, Day 21 - Day 27; Day 0 - Day 56 ]
- Serum concentrations of antibodies competitive with palivizumab (i.e., PCA) for binding to the RSV F protein. [ Time Frame: Day 0, 21, 28, 56, 119, 385 ]
- Serum IgG antibody concentrations as ELISA units (EUs) specific for the F protein antigen. [ Time Frame: Day 0, 21, 28, 56, 119, 385 ]
- Counts of IFN-γ spot forming units following in vitro stimulation of Day 0, Day 7, and Day 28 PBMC isolates with RSV F peptides. [ Time Frame: Day 0, 7, 28 ]
- Counts and proportions of Day 0, Day 7, and Day 28 peripheral blood T cells positive by intracellular staining for IL-2, IFN-γ, or TNF-α production (alone or any combination thereof) following in vitro stimulation with RSV F peptides. [ Time Frame: Day 0, 7, 28 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
-
Males and females 60 through 80 years of age who are ambulatory and live in the community or in an assisted-living facility that provides minimal assistance, such that the subject is primarily responsible for self-care and activities of daily living. Subjects may have one or more chronic medical diagnoses, but should be clinically stable as assessed by:
- Absence of changes in medical therapy within one month due to treatment failure or toxicity (dose adjustments of ongoing therapies for optimal effect, or replacements within a class of drugs due to convenience or cost, will be deemed acceptable),
- Absence of medical events qualifying as SAEs within one month of the planned vaccination on Day 0, and
- Absence of known, current, and life-limiting diagnoses which, in the opinion of the investigator, render survival to completion of the protocol unlikely.
- Willing and able (on both a physical and cognitive basis) to give informed consent prior to study enrollment. To complete the consent process, all qualifying subjects will correctly answer at least 4 out of 5 questions of the informed consent form (ICF) comprehension assessment in no more than 2 attempts.
- Able to comply with study requirements. As the protocol procedures involve telephone contacts for safety ascertainment, eligible subjects must have a reliable access to a telephone.
Exclusion Criteria:
- Received any prior RSV vaccine.
- Participation in research involving any additional investigational product (drug / biologic / device) within 45 days before planned date of first vaccination.
- History of a serious reaction to any prior vaccination or a history of Guillain-Barré syndrome (GBS) within 6 weeks of any prior influenza immunization.
- Receipt of inactivated influenza vaccine within 14 days prior to the Day 0 dose of test article or any other vaccine within the 4 weeks prior to the Day 0 dose of test article.
- Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.
- Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
- Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature ≥ 38.0°C on the planned day of vaccine administration).
- Known disturbance of coagulation. Potential subjects receiving aspirin, clopidogrel, prasugrel, dipyridamole, dabigatran, apixaban, rivaroxaban, or warfarin under good control for cardiovascular prophylaxis or prophylaxis of thromboembolic disease or stroke in the setting of atrial fibrillation will NOT be excluded.
- Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
- Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic, cognitive, or psychiatric conditions deemed likely to impair the quality of study compliance or safety reporting).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03026348
Australia, New South Wales | |
Research Site AU004 | |
Sydney, New South Wales, Australia | |
Australia, Queensland | |
Research Site AU005 | |
Herston, Queensland, Australia, 4006 | |
Australia, South Australia | |
Research Site AU002 | |
Adelaide, South Australia, Australia, 50000 | |
Australia, Victoria | |
Research Site AU006 | |
Prahran, Victoria, Australia, 3181 | |
Australia, Western Australia | |
Resarch Site AU001 | |
Nedlands, Western Australia, Australia, 6009 |
Study Director: | Vivek Shinde, MD | Novavax |
Responsible Party: | Novavax |
ClinicalTrials.gov Identifier: | NCT03026348 |
Other Study ID Numbers: |
RSV-E-205 |
First Posted: | January 20, 2017 Key Record Dates |
Last Update Posted: | August 31, 2018 |
Last Verified: | August 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
RSV |
Aluminum phosphate Vaccines Immunologic Factors Physiological Effects of Drugs |
Adjuvants, Immunologic Antacids Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents |